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Abstract 
A major limitation with current tissue engineering approaches is creating functionally 
vascularised constructs that can successfully integrate with the host; this often leads to 
implant failure due to avascular necrosis. In order to overcome this, the objective of the 
present work was to develop a method to incorporate growth-factor-eluting alginate 
microparticles (MPs) into freezedried collagen-based scaffolds. A collagen hydroxyapatite 
(CHA) scaffold, previously optimized for bone regeneration, was functionalised for the 
sustained delivery of an angiogenic growth factor (vascular endothelial growth factor-VEGF) 
with the aim of facilitating angiogenesis and enhancing bone regeneration. VEGF was 
initially encapsulated in alginate MPs by spray-drying producing particles of <10 µm in 
diameter. This process was found to effectively encapsulate and control VEGF release while 
maintaining its stability and bioactivity post-processing. These VEGF-MPs were then 
incorporated into CHA scaffolds leading to homogenous distribution throughout the 
interconnected scaffold pore structure. The scaffolds were capable of sustained release of 
bioactive VEGF for up to 35 days which was proficient at increasing tubule formation by 
endothelial cells in vitro. When implanted in vivo in a rat calvarial defect model this scaffold 
enhanced vessel formation resulting in increased bone regeneration compared to an empty 
defect and VEGF-free scaffold. This biologically functionalised scaffold, composed entirely 
of natural-based materials, may offer an ideal platform to promote angiogenesis and tissue 
regeneration.  
Keywords 
Polymeric alginate microparticles; vascular endothelial growth factor; angiogenesis; 
osteogenesis; collagen scaffolds; tissue engineering; spray-drying 
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1. Introduction 
More than 2.2 million orthopaedic procedures requiring bone grafts are conducted worldwide 
annually, making bone the second most commonly transplanted tissue next to blood (Marino 
and Ziran 2010). Due to limitations of current therapeutic approaches, the engineering and 
regeneration of bone via tissue engineered (TE) scaffolds is being explored extensively. A 
wide range of collagen-based scaffolds exist for tissue engineering (Wahl and Czernuszka 
2006; Swetha et al. 2010) a number of which have been developed and optimised in our 
research laboratory for bone repair to include synthetic ceramics and natural polymers 
(Cunniffe et al. 2010; Haugh et al. 2010; Keogh et al. 2010). These scaffolds provide a 
suitable porous structure and substrate for tissue growth by mimicking the natural 
extracellular matrix (ECM). One of the biggest challenges faced in the TE field is promoting 
the growth of vasculature within engineered tissues to enable sufficient engraftment and 
integration within the host (Novosel et al. 2011). The diffusion distance for nutrients and 
oxygen implicit to cell survival is limited (150-200µm) and this can lead to necrosis in the 
centre of the supportive scaffolds designed, for example, for bone repair. Traditional methods 
of initiating angiogenesis and osteogenesis include delivering recombinant human (Rh) 
growth factors (GFs) such as Vascular Endothelial Growth Factor (VEGF) and Bone 
Morphogenetic Proteins (BMP) (Lieberman et al. 2002) as well as direct delivery of genes 
encoding for these GFs (Lu et al. 2013). Specifically, delivery of VEGF represents a 
particularly promising means of enhancing angiogenesis and osteogenesis due to the fact that 
this protein has the ability to increase vascular network formation and vascular permeability 
(Stacker and Achen 1999) resulting in increased blood flow and access of the defect site to 
progenitor cells. Additionally, VEGF is also an inducer of osteoblast differentiation serving 
to promote cell recruitment acting as a chemo attractant for mesenchymal stem cells (MSCs), 
osteoblasts and osteogenic cells suggesting a role for VEGF in coupling angiogenesis and 
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osteogenesis (Mayr-Wohlfart et al. 2002; Patel et al. 2008). However, current GF delivery 
approaches for VEGF and other GFs are often associated with limited success due to the 
uncontrolled manner in which proteins are released, short half-life, high doses required to 
reach the target tissue, potential safety concerns within a clinical setting and high costs 
(Epstein 2011; Lu et al. 2013).  
In an attempt to overcome these issues, several scaffold-based systems either naturally 
or synthetically derived have been developed to deliver GFs to the target sites. The most 
common approach consists of GFs directly interspersed within a scaffold through soak 
loading. One example is Medtronic’s INFUSE®, a bone graft substitute consisting of an 
absorbable collagen sponge soaked with recombinant BMP-2. This product, although 
approved by the US Food and Drug Administration (FDA), has been associated with side 
effects and complications such as heterotopic bone growth or bone overgrowth as well as 
haematomas in soft tissue, para-implant bone resorption and osteolysis. This occurs as a 
result of BMP-2 leakage into other areas of the body due to the uncontrolled manner in which 
the GF is released (Epstein 2011). These shortcomings demonstrate the need for alternative 
drug delivery strategies capable of controlling growth factor delivery to particular sites. This 
has led to the emergence of scaffolds integrated with GF delivery devices in the form of 
polymer microparticles which serve to protect the GF whilst controlling its release 
(Richardson et al. 2001; Chen and Mooney 2003). The scientific literature describes an array 
of microparticle engineering methodologies for encapsulating drugs in a variety of matrix 
materials including emulsion dispersion (Borselli et al. 2010), ionotropic pregelation (Reis et 
al. 2006) and spray drying (Schoubben et al. 2010). However, emulsion dispersion and 
ionotropic gelation possess limitations in that they are difficult to scale up and typically 
involve the use of toxic organic solvents.  Spray-drying is a rapid method to produce calcium 
alginate microparticles with few processing parameters compared to other techniques making 
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it suitable for industrial scale up (Sivadas et al. 2008; Schoubben et al. 2010). In the current 
study, the encapsulation of VEGF in spraydried microparticles produced from the natural 
polymer alginate was investigated. Alginate is biodegradable, biocompatible and categorised 
in the generally regarded as safe (GRAS) classification by the FDA (George and Abraham 
2006). Furthermore, it has many possible applications in the area of drug delivery and 
controlled release (Lee and Mooney 2012).  
These spray-dried microparticles were incorporated into scaffolds with properties 
optimised specifically to promote cell infiltration and tissue formation.  Recent work in our 
laboratory has led to the development of a highly porous collagen-hydroxyapatite (CHA) 
scaffold that combines biodegradability and biocompatibility characteristics of collagen with 
the naturally occurring and osteoconductive bone mineral hydroxyapatite (Gleeson et al. 
2010). Previously this has been shown to facilitate bone regeneration in two pre-clinical 
models: rat calvaria (Gleeson et al. 2010) and rabbit radii (Lyons et al. 2014). The aim of the 
current study was thus to enhance the regenerative capacity of this scaffold through the 
incorporation of therapeutic GFs. Specifically; the scaffold was functionalised with VEGF-
releasing alginate microparticles in an attempt to engineer a material capable of localising 
and sustaining the release of VEGF over extended periods, in order to promote vascular 
ingrowth and enhance bone formation. Herein, we describe the in vitro development and 
characterisation of this functionalised CHA scaffold through the combination of the above 
materials with the ultimate aim of assessing the functionality and bioactivity of the scaffold in 
vivo.  
2. Materials and Methods 
2.1 Preparation of VEGF-loaded alginate microparticles 
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Alginate microparticles (MPs) were prepared using low viscosity alginic acid sodium salt 
from Macrocystis pyrifera (Sigma, Ireland) by a spray-drying method. Fluorescently labelled 
Bovine Serum Albumin (BSA) with a Fluorescein Isothiocyanate tag (FITC) (Sigma, Ireland) 
was initially incorporated as a model protein cargo as previously described (Sivadas et al. 
2008) to determine the protein-MP distribution within the scaffolds. RhVEGF165 (R&D 
Systems, UK) was similarly incorporated into alginate MPs. A 0.5% w/v alginate feed 
solution was mixed with VEGF (1µg/mg) and spray-dried (Buchi Mini Spray-Dryer B290) 
according to the following drying parameters: compressed air 5-8 bar, air flow rate 400-
600L/hr, inlet temperature 140 °C, aspirator at 80% of maximum capacity, and pump flow 
rate at 15%. These were based on previously established parameters for fabricating particles 
of an appropriate size range for the intended application (Sivadas et al. 2008). MPs were 
obtained in powder-form from the spray-drier and subsequently crosslinked. With this 
purpose, MPs were suspended in acetonitrile to disperse them under sonication (Schoubben et 
al. 2010) and the suspension was poured into 1.2% (w/v) calcium chloride solution under 
magnetic stirring (10 min). The particles were filtered on 0.45 µm nylon filter paper, washed 
twice with distilled water to remove the solvent and dried at room temperature overnight. The 
recovered MPs were stored at 4 ºC in a dessicator until further use.  
2.1.1 Microparticle yield and size 
The mass yield of product after spray-drying and crosslinking was determined according to 
the below equation. 
Yield (%) = mass of MPs post spraydrying (g)/ (polymer + protein in spraydryer (g) x 100 
The mean particle size and size distribution of the MPs were determined by dynamic light 
scattering (DLS) with a Malvern MasterSizer Sirocco 2000 by suspending the particles in 
distilled water prior to analysis. Size and surface morphology of the VEGF-MPs was 
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characterized using a scanning electron microscope (SMU SEM, Japan) and an optical 
microscope (Olympus CX-41). Prior to SEM observation, the particles were mounted on 
metallic studs coated with thermoplastic carbon adhesive and later sputtered with gold. 
2.1.2 VEGF loading and encapsulation efficiency 
To determine the content of VEGF encapsulated in the polymer, 5 mg of dried and 
crosslinked VEGF-MPs were dissolved in 10 mLs of 0.1 M sodium citrate under magnetic 
stirring for 30 min and the VEGF content analysed by ELISA using a rhVEGF DuoSet® 
ELISA Development kit (R&D Systems, UK) according to the manufacturer’s instructions. 
Drug loading and encapsulation efficiency were defined as: 
Loading efficiency, LE (%) = encapsulated drug/microparticle weight, 
Theoretical loading efficiency, TLE (%) = drug used for encapsulation/ (protein + polymer 
used for encapsulation), 
Encapsulation efficiency, EE (%) = LE/TLE 
2.1.3 In vitro growth factor release kinetics from microparticles 
In order to examine VEGF release kinetics from the alginate MPs, 20 mg of VEGF-MPs were 
dispersed in 2 mLs of Dulbecco’s Phosphate Buffered Saline (PBS; 140mM NaCl, 1.5mM 
KHPO4, 8.1mM NaHPO4, 2.7mM KCl; Sigma-Aldrich, Germany) placed in a waterbath and 
shaken at 37 ºC. The release medium was removed following centrifugation and replaced by 
fresh PBS at the following timepoints for analysis; 4 h, day 1, 3, 7, 14, 21 and 28. VEGF in 
the release media was quantified using the rhVEGF ELISA above according to the 
manufacturer’s instructions.  
2.2 In vitro bioactivity of VEGF released from microparticles 
2.2.1 Cell culture 
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To assess the bioactivity of VEGF released from alginate MPs, Human Umbilical Vein 
Endothelial Cells (HUVECs) were cultured in complete endothelial media (EGM-2 BulletKit, 
Lonza, UK) in T175 flasks under standard culture conditions (37 oC, 5% CO2) until they 
reached 90% confluency. Media was replaced every 3-4 days. Cells were passaged every 5-6 
days. A confluent flask was rinsed with 10 ml of pre-warmed PBS to remove any trace of 
media and trypsinised (0.25% EDTA/Trypsin (Sigma-Aldrich, Germany). Flasks were 
returned to the flow hood where 4-5 ml of medium was added to deactivate the trypsin and 
the cells were counted using a haemocytometer. The collected suspension was then 
centrifuged (5000rpm for 5 min), the supernatant was discarded and the pellet was 
resuspended in growth media without VEGF and seeded according to the below parameters. 
2.2.2 Tubule formation in response to released VEGF 
To examine the ability of VEGF released from VEGF-MPs to enhance angiogenesis, Growth 
Factor Reduced Matrigel™ (BD Biosciences, UK), a basement membrane matrix commonly 
used to observe in vitro angiogenesis, was placed in a 48 well plate (120 µL/well). The 
release media (containing VEGF) was diluted to achieve a VEGF concentration previously 
shown to enhance tubule formation (50 ng/mL) in vitro in a similar assay (Suehiro et al. 
2010). HUVECs were plated at 3x104 per well and placed in an incubator for 20 min after 
which time different cell culture media was added including; 1 mL of endothelial medium 
without the VEGF supplement in all cases, endothelial media containing VEGF previously 
released from VEGF-MPs (for 4 h) and diluted to 50 ng/mL or non encapsulated VEGF 
aliquoted from fresh VEGF stock solution at the same concentration used as a bioactivity 
benchmark control. Phase contrast light microscopy images of the cells at 10x magnification 
were captured at 6 h, 12 h and 24 h post-seeding with an in-situ camera (LEICA DFC420C) 
using a Leica DMIL microscope (Leica Microsystems, Switzerland). Image J software 
(Abramoff et al. 2004) (National Institutes of Health) was used to determine the total tubule 
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length of each tube in each image (5 images/well) and the average cumulative length per well 
was calculated in response to the various culture conditions used as a surrogate marker of 
angiogenesis. 
2.3 Fabrication and characterisation of CHA and functionalised CHA scaffolds  
Having established the method of VEGF-MP preparation and maintenance of VEGF 
bioactivity, a collagen-hydroxyapatite (CHA) scaffold was fabricated using a patented freeze-
drying process developed by the RCSI Tissue Engineering Research Group (O'Brien 2008; 
Gleeson et al. 2010; Lyons et al. 2014). Briefly, collagen (Collagen Matrix, Inc, New Jersey) 
slurries were produced by the homogenization of 1.8 g of fibrillar collagen within 320 mL of 
a 0.5 M acetic acid solution. Slurries were homogenized in a reaction vessel at 4 °C using an 
overhead blender. In parallel, 3.6 g of hydroxyapatite (HA) particles with a size 3-8 μm 
(Plasma-Biotal Ltd) were suspended in 40 mL of a 0.5 M acetic acid solution. The final CHA 
slurry (200% HA/collagen weight ratio) was produced by the addition, in aliquots, of the 
HA/acetic acid suspension to the initial collagen slurry during the homogenization process. 
The slurry was degassed under a vacuum to remove air bubbles and subsequently 9 mL was 
pippetted into a stainless steel pan (45 x 45 mm, grade 304 SS). The tray was placed into a 
freeze-dryer and cooled to -10 °C at a constant rate of 0.9 ºC/min. Once freezing was 
complete, the ice crystals were removed by sublimation for 17 h at 200 mTorr. The resulting 
materials were cut with a punch into 6.5 mm diameter discs with a depth of 3-4 mm.  
In order to incorporate the MPs into the scaffold for the formation of a functionalised 
CHA scaffold they were suspended in water for achieving three difference concentrations 
within the CHA slurry; 0 (control scaffolds), 0.5, 1.1 and 2.2% w/v (weight of 
microparticles/volume of slurry) equating to 0, 1.5, 3.3 and 6.6 µg of protein. They were then 
dispersed with the CHA slurry and freeze-dried as above. This fabrication process is the 
subject of a patent filing (O'Brien et al. 2012).  Blank and BSA-FITC loaded MPs were 
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initially incorporated to establish the maximum MP loading achievable so as not to affect the 
porosity and mechanical properties of the scaffold. VEGF-MPs were subsequently 
incorporated into the slurry at the maximum MP loading capacity, determined to be 0.5% w/v 
of CHA slurry, based on scaffold characterisation studies, according to results that are shown 
in the supplementary information. This VEGF-releasing scaffold will be denoted VEGF-MP 
scaffold in the remainder of the manuscript. Scaffolds were crosslinked under an ultra-violet 
(subtype C, 365 nm λ) lamp for 15 mins and were turned half way through to enhance the 
mechanical and enzymatic resistance properties of the materials (Weadock et al. 1995; 
Weadock et al. 1996). Scaffolds were subsequently sterilised under the UV lamp (254 nm λ).  
Confocal Laser Scanning Microscopy using a LSM 510 Axio plan 2 upright confocal 
microscope (Carl Zeiss, Germany) was used for assessing the distribution of flourescently 
labelled MPs in different layers and regions of the BSA-FITC loaded MP scaffolds and 
carrying out 3-dimensional reconstructions from these images Scaffolds were cut and 
mounted onto metallic studs with the help of carbon-based glue and sputtered with gold and 
SEM images were captured at a voltage of 5 kV using secondary electron mode, taken at a 
working distance between 12-18 mm. Both the surface and the cross-section of the MP 
scaffolds were examined.  
2.4 Analysis of VEGF release and bioactivity from VEGF-MP scaffolds  
In order to examine VEGF bioactivity following scaffold fabrication, protein was released 
from VEGF-MP scaffolds by placing 6 mm scaffolds in 2 mLs of PBS. At set timepoints; 4 
hrs, day 1, 3, 7, 14, 21, 28 and 35, buffer was removed and a fresh aliquot of PBS was added 
to the scaffold. ELISA was used for protein quantification as described above. To examine 
the ability of VEGF released from scaffolds to enhance angiogenesis, Matrigel™ was 
similarly employed as described for VEGF-MPs (section 2.2). Endothelial media containing 
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VEGF released from VEGF-MP scaffolds (for 4 h) and diluted to 50 ng/mL instead of protein 
released from VEGF-MPs, was used. 
2.5 Effect of functionalised VEGF-MP scaffolds on in vivo bone formation and 
vascularisation 
2.5.1 Surgical procedure 
In vivo analysis was conducted in accordance with protocols approved by the Research Ethics 
Committee of the Royal College of Surgeons in Ireland and an animal license was granted by 
the Irish Government Department of Health (Ref. B100/4416). A total of 24 young adult (ca. 
12 weeks) male Wistar rats (mean weight 375 g, range 360-395 g) were divided into 3 
groups: 1) empty defect (n=8) denoted ‘empty defect’ 2) CHA scaffold alone (no MPs or 
VEGF) (n=8) denoted ‘empty scaffold’, 3) CHA scaffold containing alginate MPs 
encapsulating VEGF (n=8) denoted ‘VEGF-MP scaffold’. General anaesthesia, the creation 
of the 7-mm-diameter critical-size cranial defect, the placement of the composite materials in 
the defect site, and postoperative animal care were performed using established methods in 
our lab (Lyons et al. 2010; Quinlan et al. 2015). In all cases a trephine was used to create a 
transosseous defect, confirmed by identification of the dura at surgery which remained intact. 
The rehydrated scaffold was implanted into the defect, the periosteum kept intact and 
oversewn with 3/0 absorbable monofilament suture (Ethicon, NJ, USA) and the skin closed 
with skin glue (3M™ Vetbond™ Tissue Adhesive (n-butyl cyanoacrylate)). All rats were 
housed in the Biomedical Research Facility at the Royal College of Surgeons in Ireland, 
Dublin 2, Ireland. At 8 weeks post-implantation, the animals were euthanized by CO2 
asphyxiation, a 20 x 20 mm segment of calvarium containing the defect was resected using a 
dental saw (Dentalfarm, Torino, Italy) and the explants retrieved were stored in 10% formalin 
for 4 days and then transferred to PBS prior to analysis. 
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2.5.2 Immunohistochemical staining 
The endothelial cell marker platelet endothelial cell adhesion marker (PECAM/CD31) was 
analysed to observe the ability of VEGF released from the scaffolds to promote vessel 
formation as it is highly expressed in endothelium (Zocchi et al. 1996; Norrby and Ridell 
2003). CD31 is a commonly used endothelial marker for quantifying angiogenesis by 
calculation of Microvessel Density (MVD) (Norrby and Ridell 2003). For quantification, 
cross-sections (7 µm) of decalcified, paraffin embedded tissue (described below) representing 
the peripheral and central regions of the scaffold (8 scaffolds per group with n=6 sections 
analysed per scaffold) were deparaffinized, rinsed in PBS, surrounded by a PAP pen and 
incubated in blocking buffer consisting of horse serum and 1% BSA in PBS (Vectastain Elite 
Kit, Vector laboratories, CA, USA) for 1 h. The specimens were washed in PBS/Tween 20 
and incubated in mouse anti-rat primary CD31 antibody (BD Biosciences, UK) at a dilution 
of 1:650 in 1% BSA in PBS for 1h at room temperature and then mounted with Vectashield 
(Vectastain Elite Kit). Images were taken with a fluorescence microscope (Olympus IX51-
AnalySIS imaging system) where FITC-labelled ECs in sections were visualised. Nuclei were 
stained with DAPI to identify the presence of vessel forming ECs. Vessel area is then 
measured using the DAPI images to select for vessel forming ECs subtracing any staining 
due to the presence of scaffold. Vessel area (average of the total area covered by red stained 
vessels in the sections) and density (total number of vessels found in the biomaterial) were 
quantified using ImageJ software. 
2.5.3 Microcomputed tomography analysis 
The three dimensional (3D) structure of the new bone produced within the cranial defect was 
analysed using micro computed tomography (microCT). Scans were performed on a Scanco 
Medical 40 MicroCT system (Scanco Medical, Bassersdorf, Switzerland) with 70 kVP Xray 
source and 112 µA (resolution of ~12µm). 3D reconstruction was performed using the 
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standard Scanco software package and a threshold of 140 in a scale from 0–1000. Volume of 
interest (VOI) was defined to analyze a 6 mm defect region to assess healing in the centre of 
the defect excluding any old bone at the defect edges. Repair was expressed as percentage 
bone within the defect area.  
2.5.4 Histological analysis 
Along with microCT, both qualitative and quantitative histological examinations were 
performed on explants in order to assess the levels of bone and vascular formation throughout 
the scaffold following implantation for 8 weeks. After microCT analysis, the implants were 
decalcified for 3-4 weeks depending on the level of mineralisation using 
Ethylenediaminetetraacetic acid (EDTA) 14% (w/v) at pH 7.4. The specimens were bisected, 
wax embedded, sectioned (7 µm) and stained with Haematoxylin and Eosin (H&E). Images 
were taken using transmitted light and epifluorescence microscopic visualisation (Nikon 
Microscope Eclipse 90i, Nikon Instruments Europe, The Netherlands). The defect margin 
was identified and quantitative histomorphometric analysis was carried out using a blind 
scoring method to quantify the healing response from the H&E-stained samples by 
calculating the average area of bone nucleation sites (stained pink) formed in cross-sections 
representing the peripheral and central regions of the scaffold using ImageJ (8 
scaffolds/group with n=6 sections analysed/scaffold).  
2.6 Statistical analysis 
Results are expressed as mean ± standard error of the mean (SEM). Statistics were carried out 
using GraphPad Prism software using a general linear model ANOVA followed by Tukey 
and Bonferroni post hoc analysis unless otherwise stated. The sample size was n=3 for in 
vitro and n=8 for in vivo studies where p≤0.05 values were considered statistically 
significant. 
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3. Results 
3.1 VEGF-microparticle characterisation  
A process yield after spraydrying of 54 ± 4% was determined for blank alginate and BSA-
FITC loaded MPs and 65 ± 4% for VEGF loaded MPs. Scanning electron micrographs of the 
VEGF-MPs show particles which are irregularly shaped although generally smooth and 
spherical, features which have previously been described for alginate microparticles 
fabricated by spraydrying (Bowey et al. 2013), with diameters lower than 10 µm in size (Fig. 
1A). DLS measurements confirmed these observations, as diameters of the VEGF-MPs were 
found to be distributed in the range of 1-20 µm with an average size of 3.9µm. Protein 
encapsulation efficiency of the VEGF loaded alginate MPs was next determined by relating 
the loading efficiency (0.045%) to the total theoretical loading efficiency (0.1% protein: 
polymer). The content of encapsulated protein as determined by ELISA was found to be 49 % 
of the original amount of VEGF incorporated during the fabrication process.  
3.2 Analysis of VEGF release and bioactivity from VEGF microparticles 
The release profile of VEGF from the MPs, displayed in Figure 1C, was continuous and 
sustained at high levels for up to 4 days after which time protein release dropped at 7 days. 
Following this, a decrease in VEGF release was seen thereafter from day 10 where minimum 
concentrations were recorded until the end of the study.  At the end of the study 28% of the 
protein was released cumulatively. Surprisingly, when the particles were digested at the 
endpoint of the study they were shown to still contain 20% of the initially incorporated 
protein.  
The ability of the encapsulated VEGF to stimulate the tubule formation potential of HUVECs 
was determined by culturing ECs with VEGF released from VEGF-MPs and subsequently 
quantified and diluted to 50 ng/mL. There HUVECs displayed enhanced tubule network 
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formation (6 h and 12 h) compared to the rhVEGF control (non encapsulated) added to the 
media at the same concentration. In addition, the ability of encapsulated VEGF to stimulate 
EC proliferation was also enhanced to a similar extent as the rhVEGF control when compared 
to cells in the absence of VEGF (see supplementary information). 
3.3 Characterisation of MP distribution and pore size of functionalised scaffolds  
Confocal microscopy characterisation of scaffolds incorporating BSA-FITC loaded MPs was 
used to demonstrate the uniform spreading of the MPs throughout different layers  within the 
scaffolds at all MP concentrations incorporated (see supplementary information and Figure 2 
A). Scanning electron microscopy images, displayed in Figure 2, corroborated these results, 
as they demonstrate the homogeneous distribution of the polymer particles through the 
collagen matrix. The pore diameters of the scaffolds decreased as a function of the increasing 
concentrations of MPs with pore size significantly highest (100 µm) in scaffolds containing 
the lowest MP concentration (see supplementary information). Since the optimal range of 
scaffold pore sizes for bone tissue regeneration is between 100 µm and 135 µm (Murphy and 
O'Brien 2010), scaffolds with a concentration of microparticles of 0.5% were selected for 
further studies.   
3.4 Analysis of VEGF release and bioactivity from VEGF-MP scaffolds 
The kinetics of VEGF eluted from the MPs which were incorporated within the scaffold was 
next assessed. Similarly to the delivery from the microparticles alone, the total release 
achieved at the endpoint of the study from the scaffolds was 26% (427 ng) of the initially 
incorporated VEGF (Fig. 2D). A high burst release of greater than 160 ng VEGF (10% of the 
total loaded protein) was recorded from the VEGF-MP scaffolds, in contrast to the release 
kinetics observed from the MPs alone (i.e. not embedded in a scaffold) where no burst release 
was detected. This was followed by a lower VEGF release at 24 h and a burst again of 7% of 
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loaded protein at day 4. After 4 days, a slow release of VEGF was sustained until the end of 
the assay.  
Having determined the release kinetics of VEGF from the scaffolds the next step was 
to examine whether the process of VEGF-MP scaffold preparation had any detrimental effect 
on VEGF bioactivity.  This was shown not be the case and VEGF bioactivity was retained 
following the various process parameters (Fig. 3A, B). It was observed that ECs cultured with 
VEGF released from VEGF-MP scaffolds displayed enhanced tubule network formation to a 
similar extent as rhVEGF added directly to the media at the same concentration compared to 
cells cultured in the absence of VEGF for 6 h. Regression of the tubules observed between 12 
and 24 h is a typical behaviour of these capillary-like structures as previously reported 
(Kubota et al. 1988; McCoy et al. 2013). 
3.5 Effect of functionalised scaffolds on in vivo vascularisation and bone formation 
3.5.1 Assessment of the angiogenic effect of VEGF-MP scaffolds 
The ability of the scaffolds to promote in vivo angiogenesis was evaluated by quantifying 
immunohistochemically stained endothelial cells (Fig.4A). An observably higher angiogenic 
response was evident in the VEGF-MP group correlating to a high level of neovascularisation 
compared to all other groups. Empty scaffolds had no effect on angiogenesis when compared 
to empty defects. Importantly, in the VEGF-MP group, quantitative analysis revealed a 3-fold 
increase in the number of de novo blood vessels compared with that of the empty defect (Fig. 
4C). Furthermore, the VEGF-MP scaffolds led to a 2-fold increase in vessel area compared 
with the empty defect and a 5-fold increase compared to the empty scaffold (Fig. 4D). In 
summary, these results demonstrate the ability of VEGF eluted from the functionalised 
scaffolds to enhance angiogenesis.  
3.5.2 Assessment of the osteogenic effect of VEGF-MP scaffolds 
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Having determined the angiogenic effects of the VEGF-releasing functionalised scaffold, the 
effects of the scaffold on bone formation were studied by microCT imaging (Fig. 5A) 
revealing the higher extent of new bone formation in the functionalised scaffolds when 
compared to the empty defect control (significant) and the empty scaffold (non significant) 
Fig. 5B). While the empty scaffold group also displayed higher bone volume compared to the 
empty defect the volume was reduced compared to the VEGF-MP group. To further 
characterise the levels of healing, H&E staining was carried out on explants after 8 weeks, 
results of which are shown in Figures 5C and 5D. Overall, less healing was found in the 
empty defect compared to all other groups. In the empty defect group, the defect space was 
primarily occupied by busy thin fibrotic tissue (Fig. 5C and high mag image below) and very 
little bone formation had occurred. In the empty scaffold group bone formation occurred 
predominantly at the defect edges. Cellular infiltration was seen in all scaffolds with some 
level of bridging occurring as confirmed in the microCT images of empty defect versus 
scaffold groups (Fig. 5A). In the defects treated with VEGF-MP scaffolds, enhanced bone 
regeneration was evident when compared to the CHA scaffold alone and empty defect (high 
mag images). A much thicker region of bone formation was obvious, with good cell 
infiltration throughout the construct (Fig. 5C) and high levels of bone bridging. These 
observations were further confirmed by quantitative histomorphometrical analysis 
demonstrating the enhanced area of new bone formed resulting from VEGF-MP treatment. 
This was significantly higher than in the empty defect group as well as the defects treated 
with non-VEGF eluting empty CHA scaffolds (Fig. 5D). Taken together, these data 
demonstrate the ability of the VEGF-MP scaffold to promote bone formation in vivo. 
4. Discussion 
The role of scaffolds for bone tissue repair is progressively evolving from simple support 
materials for cell growth to bioactive matrices which can also deliver pro-regenerative factors 
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to enhance tissue regeneration. The aim of this study was to deliver VEGF in a controlled and 
sustained manner from polymer microparticles embedded within a collagen-hydroxyapatite 
scaffold previously developed for bone regeneration, in order to enhance its therapeutic 
potential by increasing angiogenesis. The extensive characterization carried out in this study 
demonstrates that, with the proposed fabrication technique it is possible to create these 
functionalised scaffolds which were shown to be capable of enhancing blood vessel 
formation. In addition the VEGF-releasing functionalised scaffold also facilitated increased 
bone repair in a critically sized rat calvarial defect model. 
To the best of our knowledge, the present work describes for the first time the 
encapsulation of VEGF in alginate using a spraydrying technique and a complex multistep 
process for the subsequent incorporation of these MPs into a 3D scaffold developed for tissue 
engineering applications.  The spray-drying process was chosen since it is widely used at an 
industrial level for the manufacture of particulate systems as it enables production of small 
diameter MPs with high yields and drug encapsulation efficiencies (Hascicek et al. 2003). In 
the present work, the size of VEGF-eluting microparticles were in the range of 1-20µm, in 
accordance with alginate materials fabricated similarly (Bowey et al. 2013). Importantly, 
VEGF was released at timepoints relevant to its in vivo expression profile reported in fracture 
healing models suggesting the potential of this delivery system to mimic the innate in vivo 
response (Tsiridis et al. 2007). Furthermore, the growth factor maintained its bioactivity 
during the encapsulation process; VEGF released from the MPs was proficient at increasing 
tubule formation by ECs in vitro. Additionally, when compared with non encapsulated, fresh 
rhVEGF used as positive control, tubule formation was enhanced, probably due to alginate 
dissolving from particles into the release media which may alter the binding of VEGF to 
VEGF receptors on ECs thereby prolonging the effects (Peters et al. 1998). At the endpoint 
of the study, MPs were shown to still retain 20% of the originally loaded protein, indicating 
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physical integrity of VEGF even after 28 days in an aqueous solution. The remainder of the 
protein may have degraded to a variable extent in the PBS. Taken together, the results 
confirmed the feasibility of spray-drying as a method of MP fabrication for encapsulation of 
VEGF. Thus, these VEGF loaded MPs were incorporated into scaffolds in order to enhance 
their angiogenic capacity. Such scaffolds would possess dual functionality; they would 
enhance bone regeneration due to the osteoinductive nature of the matrix (Gleeson et al. 
2010) while providing a physical support for the MPs to release VEGF in the target tissue 
thereby promoting angiogenesis.  
The final fabrication process resulted in scaffolds with mean pore sizes greater than 
100 µm – a size range known to facilitate proliferation of osteoblasts and osteogenic 
differentiation of MSCs (Hulbert et al. 1970; O'Brien et al. 2005; Byrne et al. 2008; Murphy 
and O'Brien 2010). Furthermore the fabrication process resulted in a homogenous distribution 
of the MPs throughout the scaffold - a beneficial result which allows controlled spatial 
delivery of the GF, an effect which can be lost when particles aggregate (Langer 1998). 
Cumulative release data suggested a controlled release profile from the scaffolds with a high 
initial burst release followed by a slower release for up to 4 days after which time a steady 
state sustained VEGF delivery profile was observed. The high burst release is likely a result 
of protein being released from MPs at first contact with the acidic environment of the CHA 
slurry prior to freeze-drying. Spraydried MPs typically accumulate their cargo on the outer 
surfaces (Vehring 2008) and since MPs may partially dissolve in contact with the slurry, the 
aggregated drug on the outer surface is released in an uncontrolled manner. Although there is 
little conclusive information regarding the specific VEGF concentration required to elicit an 
in vivo biological response, it has been demonstrated that higher concentrations of VEGF for 
a period of up to 7 days followed by lower concentrations as well as a distributed pattern of 
delivery, as achieved with this scaffold, is more effective at permitting neovascularisation 
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(Stacker and Achen 1999; Street et al. 2002; Silva and Mooney 2010). Several previous 
studies using a bolus delivery method have demonstrated that doses of 10-30 ng/g resulted in 
increased neovascularisation in vivo. Other studies have shown that a lower dose of 4 ng/g of 
VEGF released from PLGA microparticles in an alginate gel was sufficient to induce 
angiogenesis in vivo (Lee and Lee 2009). The delivery system developed in this study is thus 
desirable since the kinetics achieved enabled the release of therapeutically relevant VEGF 
concentrations which may promote enhanced vasculogenesis (Pufe et al. 2002). Another 
critically important characteristic of the delivery system is its ability to maintain the 
bioactivity of the GF pre- and post-processing. The results demonstrated that VEGF released 
from the MPs enhanced tubule network formation by endothelial cells suggesting that 
alginate encapsulation provided protection to degradation from the acidic environment of the 
scaffold slurry and during the freezedrying process. Taken together, these encouraging results 
demonstrate that a fabrication process for scaffolds showing spatiotemporally controlled GF 
delivery was developed.   
The functionalised scaffold was shown to enhance angiogenesis and bone 
regeneration in a critically sized rat calvarial defect model by 8 weeks post- implantation. 
Since angiogenesis involves the movement of ECs towards gradients of VEGF, it is likely 
that the scaffold sustained sufficient VEGF gradients across the scaffold-tissue interface to 
elicit an enhanced biological response in vivo. In addition to the number of vessels increasing, 
the size of the vessels was shown to increase in the VEGF-functionalised scaffold. It is likely 
that some of these large vessels were derived from newly formed capillaries resulting from 
increased vessel density in the VEGF-MP group. VEGF release from the material may have 
indirectly increased bone formation as a consequence of increasing blood flow in the defect 
site by laying down a supportive vascular network. Furthermore, the ability of VEGF to 
promote chemotaxis and differentiation of osteoblasts is known (Patel et al. 2008) and is 
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consistent with previous studies which showed that the release of VEGF from biomaterials 
can enhance bone regeneration in critical sized defects (Geiger et al. 2005; Kaigler et al. 
2006; Clarke et al. 2007; Wernike et al. 2010). The potential of CHA scaffolds to promote 
mineralisation within a calvarial defect has previously been demonstrated. Histomorphometry 
revealed that functionalised scaffolds significantly enhanced bone repair compared to the 
non-VEGF eluting empty CHA scaffolds. The discrepancy between this result and the 
microCT analysis, which demonstrated a non-significant enhancement in bone volume in the 
functionalised scaffolds compared to the empty scaffold control, may be explained by the 
higher area of mature bone compared to earlier mineralised tissue in the microCT analysis. 
Nonetheless, this study has shown that controlled VEGF release led to increased vessel 
density and vessel size, accompanied by de novo bone formation and early bone healing of a 
critically sized bone defect.  
The functionalised scaffolds described herein represent a promising approach for 
overcoming the associated problems of uncontrolled drug delivery for tissue engineering. 
Both the spray drying and the freeze-drying techniques, used for the fabrication of MPs and 
the scaffolds respectively are reproducible processes which can be easily scaled up to 
industrial production (I Ré 1998; George and Abraham 2006). Another potential avenue 
which could be explored is the adaptability of this pro-angiogenic material to a range of other 
applications to enhance vascularisation in ischemic tissues. Freeze-dried collagen-based 
scaffolds are currently being used for the regeneration of a wide range of tissues, such as 
cartilage (De Franceschi et al. 2005), cornea (Griffith et al. 2009) and blood vessels 
(Buttafoco et al. 2006). Thus, this system has an enormous potential in regenerative 
medicine, as it could be tuned in terms of the composition of the collagen-based scaffold and 
released therapeutic to be optimized for the healing of very diverse organs. 
5. Conclusion 
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This study demonstrated the successful fabrication of a novel functionalised collagen-based 
scaffold capable of the spatiotemporal controlled release of VEGF through the incorporation 
of spray-dried alginate microparticles. The procedure for functionalising these scaffolds 
maintained VEGF bioactivity as it was proficient at increasing tubule formation by 
endothelial cells in vitro. These functionalised scaffolds were capable of sustaining the 
release of VEGF for up to 35 days. When implanted in vivo in a rat calvarial bone defect 
model this functionalised scaffold led to enhanced vessel formation after 8 weeks. In 
addition, the release of VEGF also resulted in increased bone regeneration. The process 
developed to functionalise these scaffolds, may offer an ideal platform to promote 
angiogenesis and tissue regeneration for a wide variety of applications in addition to bone.  
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Fig. 1 Microparticle characterisation. (A) Scanning electron micrograph of VEGF-MPs 
prepared by the spraydrying method showing particle sizes <10µm. Scale bars, 10 µm. (B) 
Microparticle size distribution indicating particle diameters in the range of <10 µm. (C) 
Cumulative VEGF release from alginate MPs.  
 
Fig. 2 Microparticle scaffold composition and VEGF release. (A) Confocal image of alginate 
microparticles encapsulating BSA-FITC in a scaffold. Scale bar, 100 µm. (B) Scanning 
electron micrographs of surface and (C) cross sections of scaffolds incorporating 0.5% w/v 
alginate VEGF microparticles (1.6 µg of VEGF). Scale bars, 10 µm. (D) Cumulative VEGF 
release from VEGF-MP scaffolds over 35 days.  
 
Fig. 3 Bioactivity of VEGF released from VEGF-MP scaffold in a tubule formation assay. 
(A) Microscopy images depicting tubule formation after 6 h in culture demonstrating 
enhanced tubule formation in the VEGF released from VEGF-MP scaffold groups. Scale 
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bars, 100 µm. (B) Quantification of tubule formation corroborating images taken at 6 h. ** 
p<0.01; * p<0.05 vs no VEGF control. 
 
Fig. 4 Immunohistochemical analysis of vascular network formation. (A) CD31 labelled 
endothelial cells and (B) DAPI stained nuclei in sections of empty defect, empty scaffold and 
VEGF-MP scaffolds indicating enhanced vessel density (white arrow) in VEGF-MP groups 
compared to the controls at 8 weeks. Scale bars, 50 µm. (C) Vessel density in implants 
indicating an increase in the VEGF-MP group compared to the empty defect (* p<0.05) and 
empty scaffold. (D) Total area of new vessel formation indicating an increase in the VEGF-
MP group compared the empty defect (** p<0.01) and empty scaffold (*** p<0.001). One-
way ANOVA and post-hoc Tukey post-test performed. 
 
Fig. 5 Microcomputed tomographical analysis and histomorphometrical analysis of explants 
demonstrating the level of bone repair. (A) Qualitative and (B) quantitative microcomputed 
tomographical analysis of empty defect, empty scaffold and VEGF-MP scaffolds at 8 weeks 
post-implantation demonstrating that the VEGF-MP group supported the highest level of 
bone formation compared to empty defect (** p<0.01) and empty scaffold (* p<0.05). One-
way ANOVA and post-hoc Tukey post-test performed. (C) Haematoxylin and eosin stained 
sections of empty defect, empty scaffold and VEGF-MP scaffolds showing the full specimen 
with the original host bone (hb) (top panels). Fibrotic tissue (ft) is visible in the empty defect 
while a layer of bone formation with mineralised tissue (black arrows) is visible in the empty 
scaffold and a dense layer of bone formation is seen in the VEGF-MP group with woven 
bone (wb) visible (bottom panels at 20x mag). Scale bars, 50 µm. (D) Quantitative 
histomorphometric analysis indicating the mean total area of bone nucleation sites and 
accelerated bone healing in VEGF-MP scaffolds compared to empty scaffolds and empty 
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defect (*** p<0.001). One-way ANOVA and Dunns Multiple Comparison post-test 
performed. 
 
 
